Chronic myeloid leukemia and allogeneic natural killer cells: a surprising dialogue

References

• Rowley JD. Chromosomal patterns in myelocytic leukemia. N. Engl. J. Med.289, 220–221 (1973).
   PubMed Web of Science ®Google Scholar
• Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood88, 2375–2384 (1996).
   PubMed Web of Science ®Google Scholar
• Issaad C, Ahmed M, Novault S et al. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7. Leukemia14(4), 662–670 (2000).
   PubMed Web of Science ®Google Scholar
• Barnes DJ, Schultheis B, Adedeji S, Melo JV. Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia. Oncogene24, 6432–6440 (2005).
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N. Engl. J. Med.340, 1330–1340 (1999).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. Chronic myelogenous leukemia. Hematology Am. Soc. Hematol. Educ. Program87–112 (2001).
   PubMedGoogle Scholar
• Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med.344(14), 1031–1037 (2001).
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood99(6), 1928–1937 (2002).
   PubMed Web of Science ®Google Scholar
• Mauro MJ, O’Dwyer ME, Druker BJ. ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy. Cancer Chemother. Pharmacol.48(Suppl. 1), S77–S78 (2001).
   PubMed Web of Science ®Google Scholar
• O’Dwyer M, Druker B. STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia. Lancet Oncol.1, 207–211 (2000).
   PubMedGoogle Scholar
• Margolis J, Borrello I, Flinn I. New approaches to treating malignances with stem cell transplantation. Semin. Oncol.27, 524–530 (2000).
   PubMed Web of Science ®Google Scholar
• Luznik L, Fuchs E. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control9, 123–137 (2002).
   PubMedGoogle Scholar
• Farag S, Fehniger T, Ruggeri L, Velardi A, Caligiuri M. Natural killer cells: biology and application in stem-cell transplantation. Cytotherapy4, 445–446 (2002).
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood94(1), 333–339 (1999).
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science295(5562), 2097–2100 (2002).
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Biology of natural killer cells. Adv. Immunol.47, 187–376 (1989).
   PubMed Web of Science ®Google Scholar
• Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med.155, 1823–1841 (1982).
   PubMed Web of Science ®Google Scholar
• Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol. Today11, 237–244 (1990).
   PubMedGoogle Scholar
• Moretta A, Bottino C, Vitale M et al. Receptors for HLA class-I molecules in human natural killer cells. Ann. Rev. Immunol.14, 619–648 (1996).
   PubMed Web of Science ®Google Scholar
• Moretta A, Bottino C, Millo R, Biassoni R. HLA-specific and non-HLA-specific human NK receptors. Cur.r Top. Microbiol. Immunol.244, 69–84 (1999).
   PubMed Web of Science ®Google Scholar
• Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J.23, 255–259 (2004).
   PubMed Web of Science ®Google Scholar
• Moretta A, Biassoni R, Bottino C, Mingari M, Moretta L. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol. Today21, 228–234 (2000).
   PubMedGoogle Scholar
• Cooper M, Fehniger T, Caligiuri M. The biology of human natural killer-cell subsets. Trends Immunol.22, 633–640 (2001).
   PubMed Web of Science ®Google Scholar
• Billadeau D, Upshaw J, Schoon R, Dick C, Leibson P. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat. Immunol.4, 557–564 (2003).
   PubMed Web of Science ®Google Scholar
• Lanier L. Natural killer cell receptors and MHC class I interactions. Curr. Opin. Immunol.9, 126–131 (1997).
   PubMed Web of Science ®Google Scholar
• Braud V, Allan DS, O’Callaghan CA et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature391(6669), 795–799 (1998).
   PubMed Web of Science ®Google Scholar
• Davis D, Chiu I, Fassett G, Mandelboim O, Strominger J. The human natural killer cell immune synapse. Proc. Natl Acad. Sci. USA96, 15062–15067 (1999).
   PubMed Web of Science ®Google Scholar
• Davis DM. Assembly of the immunological synapse for T cells and NK cells. Trends Immunol.23, 356–363 (2002).
   PubMed Web of Science ®Google Scholar
• Vyas YM, Mehta KM, Morgan M et al. Spatial organization of signal transduction molecules in the NK cell immune synapses during MHC class I-regulated noncytolytic and cytolytic interactions. J. Immunol.167(8), 4358–4367 (2001).
   PubMed Web of Science ®Google Scholar
• Vyas YM, Maniar H, Dupont B. Visualization of signaling pathways and cortical cytoskeleton in cytolytic and noncytolytic natural killer cell immune synapses. Immunol. Rev.189, 161–178 (2002).
   PubMed Web of Science ®Google Scholar
• Pierson BA, Miller JS. CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood88, 2279–2287 (1996).
   PubMed Web of Science ®Google Scholar
• Cho EK, Heo DS, Seol JG et al. Ontogeny of natural killer cells and T cells by analysis of BCR-ABL rearrangement from patients with chronic myelogenous leukaemia. Br. J. Haematol.111(1), 216–222 (2000).
   PubMed Web of Science ®Google Scholar
• Verfaillie C, Kay N, Miller W, McGlave P. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood76, 401–408 (1990).
   PubMed Web of Science ®Google Scholar
• Miller JS, Verfaillie C, McGlave P. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture. Blood80, 2182–2187 (1992).
   PubMed Web of Science ®Google Scholar
• Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity4, 329–336 (1996).
   PubMed Web of Science ®Google Scholar
• Miller JS, Alley KA, McGlave P. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor. Blood83, 2594–2601 (1994).
   PubMed Web of Science ®Google Scholar
• Mrozek E, Anderson P, Caligiuri M. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood87, 2632–2640 (1996).
   PubMed Web of Science ®Google Scholar
• Carayol G, Robin C, Bourhis JH et al. NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions. Eur. J. Immunol.28(6), 1991–2002 (1998).
   PubMed Web of Science ®Google Scholar
• Yu H, Fehniger TA, Fuchshuber P et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood92(10), 3647–3657 (1998).
   PubMed Web of Science ®Google Scholar
• Carayol G, Giron-Michel J, Azzarone B et al. Altered natural killer cell differentiation in CD34+ progenitors from chronic myeloid leukemia patients. Oncogene19(23), 2758–2766 (2000).
   PubMed Web of Science ®Google Scholar
• Nakajima H, Zhao R, Lund TC et al. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients. J. Immunol.168(2), 643–650 (2002).
   PubMed Web of Science ®Google Scholar
• Komatsu F, Moriyama K. Lymphokine-activated killer cells can discriminate CD34+ leukemia cells from normal hematopoietic progenitor cells. J. Hematother.5, 49–56 (1996).
   PubMedGoogle Scholar
• Silla LM, Pincus SM, Locker JD et al. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets. Br. J. Haematol.93(2), 375–385 (1996).
   PubMed Web of Science ®Google Scholar
• Roger R, Issaad C, Pallardy M et al. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood87(3), 1113–1122 (1996).
   PubMed Web of Science ®Google Scholar
• Baron F, Turhan AG, Giron-Michel J et al. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression. Blood99(6), 2107–2113 (2002).
   PubMed Web of Science ®Google Scholar
• Burchert A, Cai D, Hofbauer LC et al. Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2. Blood103(9), 3480–3489 (2004).
   PubMed Web of Science ®Google Scholar
• Tamura T, Kong HJ, Tunyaplin C, Tsujimura H, Calame K, Ozato K. ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. Blood102(13), 4547–4554 (2003).
   PubMed Web of Science ®Google Scholar
• Cebo C, Voutsadakis IA, Da Rocha S et al. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets. Cancer Res.65(7), 2914–2920 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt M, Hochhaus A, Konig-Merediz SA et al. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy. J. Clin. Oncol.18, 3331–3338 (2000).
   PubMed Web of Science ®Google Scholar
• Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood97, 3648–3650 (2001).
   PubMed Web of Science ®Google Scholar
• Malmberg K, Levitsky V, Norell H et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J. Clin. Invest.110(10), 1515–1523 (2002).
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Kant S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest.111, 639–647 (2003).
   PubMed Web of Science ®Google Scholar
• Burchert A, Wolfl S, Schmidt M et al. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood101, 259–264 (2003).
   PubMed Web of Science ®Google Scholar
• Cebo C, Da Rocha S, Wittnebel S et al. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of nkg2d ligands, gm1 expression, and synapse formation. J. Immunol.176, 864–872 (2006).
   PubMed Web of Science ®Google Scholar
• Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature436, 1186–1190 (2005).
   PubMed Web of Science ®Google Scholar
• Fernandez NC, Lozier A, Flament C et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med.5, 405–411 (1999).
   PubMed Web of Science ®Google Scholar
• Valteau-Couanet D, Leboulaire C, Maincent K et al. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood100, 2554–2561 (2002).
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Munz C. NK cell compartments and their activation by dendritic cells. J. Immunol.172, 1333–1339 (2004).
   PubMed Web of Science ®Google Scholar
• Zitvogel L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J. Exp. Med.195, F9–F14 (2002).
   PubMed Web of Science ®Google Scholar
• Borg C, Jalil A, Laderach D et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood104, 3267–3275 (2004).
   PubMed Web of Science ®Google Scholar
• Smit WM, Rijnbeek M, van Bergen CA et al. Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells. Hum. Immunol.53, 216–223 (1997).
   PubMed Web of Science ®Google Scholar
• Dietz AB, Bulur PA, Erickson MR et al. Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells. J. Hematother. Stem Cell Res.9, 95–101 (2000).
   PubMedGoogle Scholar
• Eisendle K, Wolf D, Gastl G, Kircher-Eibl B. Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features. Leuk. Lymphoma46, 663–670 (2005).
   PubMed Web of Science ®Google Scholar
• Terme M, Borg C, Guilhot F et al. BCR/ABL promotes dendritic cell-mediated natural killer cell activation. Cancer Res.65, 6409–6417 (2005).
   PubMed Web of Science ®Google Scholar
• Dupont B, Hsu KC. Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation. Curr. Opin. Immunol.16, 634–643 (2004).
   PubMed Web of Science ®Google Scholar
• Borg C, Terme M, Taieb J et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J. Clin. Invest.114, 379–388 (2004).
   PubMed Web of Science ®Google Scholar
• Taieb J, Maruyama K, Borg C, Terme M, Zitvogel L. Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood103, 1966–1967; author reply 1967 (2004).
   PubMed Web of Science ®Google Scholar
• Mortier E, Quemener A, Vusio P et al. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J. Biol. Chem.281, 1612–1619 (2006).
   PubMed Web of Science ®Google Scholar
• Giron-Michel J, Giuliani M, Fogli M et al. Membrane-bound and soluble IL-15/IL-15Rα complexes display differential signaling and functions on human hematopoietic progenitors. Blood106, 2302–2310 (2005).
   PubMed Web of Science ®Google Scholar
• Giron-Michel J, Caignard A, Fogli M et al. Differential STAT3, STAT5, and NF-kappaB activation in human hematopoietic progenitors by endogenous interleukin-15: implications in the expression of functional molecules. Blood102, 109–117 (2003).
   PubMed Web of Science ®Google Scholar
• Giron-Michel J, Fogli M, Gaggero A et al. Detection of a functional hybrid receptor gammac/GM-CSFRbeta in human hematopoietic CD34+ cells. J. Exp. Med.197, 763–775 (2003).
   PubMed Web of Science ®Google Scholar
• Carson WE, Fehniger TA, Haldar S et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest.99, 937–943 (1997).
   PubMed Web of Science ®Google Scholar
• Ferlazzo G, Pack M, Thomas D et al. Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. Proc. Natl Acad. Sci. USA101, 16606–16611 (2004).
   PubMed Web of Science ®Google Scholar
• Alpdogan O, Eng JM, Muriglan SJ et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood105, 865–873 (2005).
   PubMed Web of Science ®Google Scholar
• Passweg JR, Tichelli A, Meyer-Monard S et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia18, 1835–1838 (2004).
   PubMed Web of Science ®Google Scholar
• Passweg JR, Stern M, Koehl U, Uharek L, Tichelli A. Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant.35, 637–643 (2005).
   PubMed Web of Science ®Google Scholar
• Miller JS, Soignier Y, Panoskaltsis-Mortari A et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood105, 3051–3057 (2005).
   PubMed Web of Science ®Google Scholar
• Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med.339, 1186–1193 (1998).
   PubMed Web of Science ®Google Scholar